NIH Websites Are Changing

NIH is moving the launch of its new website to the fall to ensure the best possible experience for everyone who relies on our websites for health information, research, funding opportunities, and other resources.

NCI-COG Pediatric MATCH Trial: Treatment Determined by Tumor Targets

April 26, 2018 (Noon - 1:30 p.m. ET)

Sponsor/Co-Sponsor(s)

Obstetric and Pediatric Pharmacology and Therapeutics Branch (OPPTB), Best Pharmaceuticals for Children Act (BPCA), NICHD

Location

NIH Neuroscience Center Building, 6001 Executive Blvd, Room B1/B2, Rockville, MD

Purpose

Although research has improved outcomes for children and adolescents with cancer, challenges remain. Precision medicine trials for pediatric cancer patients are ongoing. Pediatric MATCH is a nationwide trial to explore whether targeted therapies are effective for children and adolescents with solid tumors that have specific genetic mutations. The National Cancer Institute (NCI) and the Children’s Oncology Group, a member of NCI’s National Clinical Trials Network, developed the trial with input from the Food and Drug Administration and pharmaceutical companies. The trial is the first pediatric precision medicine trial of this scale.

Nita Seibel, M.D., will discuss Pediatric Match and related research. She is a board-certified pediatric hematologist-oncologist and the head of NCI’s Pediatric Solid Tumor Therapeutics program.

Contact

George Giacoia, OPPTB, NICHD
Phone: (301) 496-5589
E-mail: giacoiag@mail.nih.gov

Please note: Views expressed during NICHD-sponsored events do not necessarily reflect the opinions or the official positions of NICHD, NIH, or HHS.